175 related articles for article (PubMed ID: 32815876)
1. NUP98-NSD1 Driven MDS/MPN in Childhood Masquerading as JMML.
Behnert A; Lee AG; Young EP; Breese MR; Leung SG; Behroozfard I; Maruffi M; Sweet-Cordero EA; Dvorak CC; Chu J; Stieglitz E
J Pediatr Hematol Oncol; 2021 Aug; 43(6):e808-e811. PubMed ID: 32815876
[TBL] [Abstract][Full Text] [Related]
2. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
3. Juvenile myelomonocytic leukemia with t(7;11)(p15;p15) and NUP98-HOXA11 fusion.
Mizoguchi Y; Fujita N; Taki T; Hayashi Y; Hamamoto K
Am J Hematol; 2009 May; 84(5):295-7. PubMed ID: 19338047
[TBL] [Abstract][Full Text] [Related]
4. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
Talati C; Padron E
Curr Hematol Malig Rep; 2016 Dec; 11(6):425-433. PubMed ID: 27664113
[TBL] [Abstract][Full Text] [Related]
5. Mutational landscape of Juvenile Myelomonocytic Leukemia (JMML)-A real-world context.
Nathany S; Chatterjee G; Ghai S; Moulik NR; Shetty D; Subramanian PG; Tembhare P; Gujral S; Dhamne C; Banavali S; Narula G; Patkar N
Int J Lab Hematol; 2021 Dec; 43(6):1531-1538. PubMed ID: 34387930
[TBL] [Abstract][Full Text] [Related]
6. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
7. Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia.
Loh ML
Hematology Am Soc Hematol Educ Program; 2010; 2010():357-62. PubMed ID: 21239819
[TBL] [Abstract][Full Text] [Related]
8. Integrated molecular profiling of juvenile myelomonocytic leukemia.
Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
[TBL] [Abstract][Full Text] [Related]
9. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.
Chang TY; Dvorak CC; Loh ML
Blood; 2014 Oct; 124(16):2487-97. PubMed ID: 25163700
[TBL] [Abstract][Full Text] [Related]
10. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
11. [Progress in research of the pathogenesis of childhood MDS/MPN].
Yoshida K
Rinsho Ketsueki; 2018; 59(10):2284-2289. PubMed ID: 30305537
[TBL] [Abstract][Full Text] [Related]
12. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
Rudelius M; Weinberg OK; Niemeyer CM; Shimamura A; Calvo KR
Virchows Arch; 2023 Jan; 482(1):113-130. PubMed ID: 36445482
[TBL] [Abstract][Full Text] [Related]
13. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
14. Genomics of myelodysplastic/myeloproliferative neoplasm.
Patwardhan PP; Aarabi M; Aggarwal N
Semin Diagn Pathol; 2023 May; 40(3):195-201. PubMed ID: 37105794
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia.
Loh ML
Br J Haematol; 2011 Mar; 152(6):677-87. PubMed ID: 21623760
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetics of MDS/MPN overlap syndromes.
Hunter AM; Padron E
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101195. PubMed ID: 33038984
[TBL] [Abstract][Full Text] [Related]
17. De novo childhood myelodysplastic/myeloproliferative disease with unique molecular characteristics.
Ismael O; Shimada A; Hama A; Elshazley M; Muramatsu H; Goto A; Sakaguchi H; Tanaka M; Takahashi Y; Yinyan X; Fukuda M; Miyajima Y; Yamashita Y; Horibe K; Hanada R; Ito M; Kojima S
Br J Haematol; 2012 Jul; 158(1):129-37. PubMed ID: 22571758
[TBL] [Abstract][Full Text] [Related]
18. Juvenile myelomonocytic leukaemia: a case series.
Azma RZ; Zarina AL; Hamidah A; Jamal R; Sharifah NA; Ainoon O; Hamidah NH
Malays J Pathol; 2009 Dec; 31(2):121-8. PubMed ID: 20514855
[TBL] [Abstract][Full Text] [Related]
19. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Tiu RV; Sekeres MA
Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
[TBL] [Abstract][Full Text] [Related]
20. Juvenile myelomonocytic leukemia with t(3;5)(q25;q35), Auer rods and marked myelodysplasia.
Li W; Cooley LD; August K
Pathol Res Pract; 2018 Jun; 214(6):919-923. PubMed ID: 29496305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
